Jefferies Lifts Target on Solazyme (SZYM) on Q3 'Beat'
Tweet
Share
E-mailGet Alerts SZYM Hot Sheet
Price: $2.15 --0%
Rating Summary:
5 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
5 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Jefferies boosted its price target on Buy-rated Solazyme (NASDAQ: SZYM) from $22 to $23 following Q3 EPS that beat by 6 cents.
The firm comments, "The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."
Q4 EPS goes down from ($0.35) to ($0.40).
For an analyst ratings summary and ratings history on Solazyme click here. For more ratings news on Solazyme click here.
Shares of Solazyme closed at $7.09 yesterday.
The firm comments, "The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."
Q4 EPS goes down from ($0.35) to ($0.40).
For an analyst ratings summary and ratings history on Solazyme click here. For more ratings news on Solazyme click here.
Shares of Solazyme closed at $7.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- Stella International Holdings (1836:HK) (SLNLF) PT Lowered to HK$10 at Macquarie
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
